Tvardi Therapeutics (NASDAQ:TVRD) Raised to Strong-Buy at Lucid Cap Mkts

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by Lucid Cap Mkts to a “strong-buy” rating in a research note issued on Tuesday, Zacks reports.

Several other brokerages also recently issued reports on TVRD. HC Wainwright started coverage on Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 price target for the company. Piper Sandler raised shares of Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research report on Wednesday, July 8th. Wall Street Zen downgraded shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, August 30th. BTIG Research lowered their price target on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tvardi Therapeutics Stock Up 1.6%

Shares of NASDAQ TVRD opened at $1.94 on Tuesday. The business’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $2.94. The company has a market cap of $25.88 million, a PE ratio of -0.70 and a beta of 0.32. Tvardi Therapeutics has a twelve month low of $1.50 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, research analysts anticipate that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Tvardi Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TVRD. GSA Capital Partners LLP acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $34,000. Arax Advisory Partners increased its position in shares of Tvardi Therapeutics by 277.2% in the fourth quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock worth $36,000 after purchasing an additional 6,173 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Tvardi Therapeutics in the second quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the second quarter valued at about $43,000. Finally, HRT Financial LP acquired a new position in Tvardi Therapeutics in the fourth quarter valued at about $47,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.